Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS.
OBJECTIVE
To determine the safety and efficacy of liposomal amphotericin B (AmBisome) in the primary treatment of AIDS-associated cryptococcosis.


METHODS
A Phase II, multicentre, European, non-comparative, open study to assess the use of AmBisome in 23 patients (26 enrolments) with cryptococcosis. Dose requirements, mycological response and toxicity were documented.


METHODS
Hospital-based HIV units.


METHODS
Twenty-three HIV-1-seropositive patients.


RESULTS
Drug toxicity, assessed in 25 enrolments, was well-tolerated with little renal, hepatic or haematological toxicity. Eighteen out of 23 (78%) enrolments responded clinically. Nineteen enrolments had cryptococcal meningitis: sterilization of spinal fluid was achieved in 12 out of the 18 (67%) who were mycologically evaluable. Fourteen out of the 19 (74%) responded clinically.


CONCLUSIONS
AmBisome is well-tolerated and may be an effective formulation in the treatment of cryptococcosis.
Coker
R J
RJ
St Mary's Hospital, London, UK.
Viviani
M
M
Gazzard
B G
BG
Du Pont
B
B
Pohle
H D
HD
Murphy
S M
SM
Atouguia
J
J
Champalimaud
J L
JL
Harris
J R
JR
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000401:mortality; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001826:Body Fluids / Q000382:microbiology; D003453:Cryptococcosis / Q000150:complications / Q000188:drug therapy*; D003455:Cryptococcus neoformans / Q000302:isolation & purification; D004337:Drug Carriers; D015497:HIV-1; D006801:Humans; D007958:Leukocyte Count; D015993:Life Tables; D008081:Liposomes; D008297:Male; D016919:Meningitis, Cryptococcal / Q000134:cerebrospinal fluid / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D016019:Survival Analysis
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B